ArticleCureus2025
Immediate and Intermediate-Term Outcomes of Right Ventricular Outflow Tract Interventions in Neonates and Infants: A Prospective Single-Center Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRight ventricular outflow tract (RVOT) anomalies in neonates and infants necessitate early intervention to restore adequate pulmonary blood flow and promote pulmonary artery (PA) growth. This study aimed to evaluate the immediate and intermediate-term outcomes of various transcatheter RVOT interventions in this vulnerable population.
methodsThis prospective, single-center descriptive study enrolled 52 infants (aged <1 year) undergoing balloon pulmonary valvotomy (BPV, n=29), RVOT perforation with BPV and patent ductus arteriosus (PDA) stenting (n=11), or RVOT stenting (n=12) between February 2021 and November 2022. Key immediate outcomes included hemodynamic changes, procedural success, and in-hospital complications. Intermediate outcomes at three and six months assessed oxygen saturation (SpO2), weight gain, PA growth, and re-intervention rates.
resultsOverall six-month survival was high at 96.2% (50/52), with minimal procedural complications, which included two transient arrhythmias. In-hospital mortalities occurred in one BPV patient and one RVOT perforation patient, both attributed to non-procedural causes such as septic shock. BPV procedures achieved significant reductions in RV pressure (from 106±26.18 mmHg to 40.74±9.91 mmHg, p=0.04) and RVOT gradient (from 85.41±26.04 mmHg to 15.67±4.2 mmHg, p<0.0001), with a 14.3% re-intervention rate for restenosis by three months. For RVOT perforation with BPV and PDA stenting, there was marked hemodynamic improvement, with RV pressure decreasing from 105.36±18.98 mmHg to 40±12.06 mmHg (p<0.0001) and robust PA growth (RPA measuring 5.72±1.13 mm and LPA 5.10±0.93 mm at six months). Lastly, RVOT stenting was 100% successful, significantly improving SpO2 (from 73.83±5.46% to 86.83±4.61% at discharge) and enabling five infants to become candidates for complete intracardiac repair by six months.
conclusionTranscatheter RVOT interventions are safe and effective strategies for managing RVOT anomalies in neonates and infants. These intervention strategies offer targeted benefits and improve clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.